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The Parkinson’s phenome—traits associated with Parkinson’s
disease in a broadly phenotyped cohort
Karl Heilbron1, Alastair J. Noyce2,3, Pierre Fontanillas1, Babak Alipanahi 1, Mike A. Nalls4,5, The 23andMe Research Team and
Paul Cannon1
In order to systematically describe the Parkinson’s disease phenome, we performed a series of 832 cross-sectional case-control
analyses in a large database. Responses to 832 online survey-based phenotypes including diseases, medications, and
environmental exposures were analyzed in 23andMe research participants. For each phenotype, survey respondents were used to
construct a cohort of Parkinson’s disease cases and age-matched and sex-matched controls, and an association test was performed
using logistic regression. Cohorts included a median of 3899 Parkinson’s disease cases and 49,808 controls, all of European ancestry.
Highly correlated phenotypes were removed and the novelty of each signiﬁcant association was systematically assessed (assigned
to one of four categories: known, likely, unclear, or novel). Parkinson’s disease diagnosis was associated with 122 phenotypes. We
replicated 27 known associations and found 23 associations with a strong a priori link to a known association. We discovered 42
associations that have not previously been reported. Migraine, obsessive-compulsive disorder, and seasonal allergies were
associated with Parkinson’s disease and tend to occur decades before the typical age of diagnosis for Parkinson’s disease. The
phenotypes that currently comprise the Parkinson’s disease phenome have mostly been explored in relatively small purpose-built
studies. Using a single large dataset, we have successfully reproduced many of these established associations and have extended
the Parkinson’s disease phenome by discovering novel associations. Our work paves the way for studies of these associated
phenotypes that explore shared molecular mechanisms with Parkinson’s disease, infer causal relationships, and improve our ability
to identify individuals at high-risk of Parkinson’s disease.
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INTRODUCTION
The clinical diagnosis of PD is based on its canonical motor
symptoms, but there has recently been a growing understanding
of the importance of early non-motor aspects of PD such as
anxiety, constipation, and fatigue.1 In addition to motor and non-
motor prodromal symptoms, epidemiological studies have uncov-
ered a collection of traits, environmental exposures, and
comorbidities (we will collectively refer to these as “phenotypes”)
that are associated with PD, including reduced coffee consump-
tion, reduced tobacco use, reduced serum uric acid levels, and
increased rates of melanoma.2 However, the prevalence of PD is
approximately 1% in individuals over 65 years old3 making it
difﬁcult to amass the large numbers of cases required to detect
more subtle associations using traditional observational study
methods.
Large electronic databases of medical records, billing codes,
insurance claims, and prescriptions have enabled studies with
larger sample sizes and a wider diversity of phenotypes under
consideration.4,5 However, these databases are often restricted to
billable events and may not capture phenotypes related to sub-
clinical symptoms, behavior, lifestyle, morphology, or over-the-
counter medication.
Here, we sought to describe the broad spectrum of phenotypes
associated with PD—the PD phenome—using a cross-sectional
database that included 13,546 PD cases, >1.3 million controls, and
832 phenotypes including diagnoses, family history, medication
usage, environmental exposures, and behaviors. We performed
association tests using logistic regressions on age-matched and
sex-matched case–control cohorts. We used literature reviews to
classify signiﬁcant associations into four categories: known, likely,
unclear, and novel associations. Although cross-sectional data are
not well-suited for inferring causal relationships, we discuss how
our hypothesis-generating approach has meaningfully extended
our understanding of the PD phenome.
RESULTS
Demographics
Table 1 shows demographic descriptive statistics for cohorts of up
to 13,196 PD cases and 148,176 age-matched and sex-matched
controls. Cases and controls were similar with respect to age, sex,
education, and income index. We found larger differences for
body mass index (BMI) and tobacco use. The median BMI of PD
cases was 3.1% lower than that of controls and PD cases were less
likely to have ever smoked more than 100 cigarettes (cases: 38.4%,
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controls: 46.8%). Since different subsets of 23andMe research
participants responded to each survey question, we constructed
separate matched case–control cohorts for each of the 832
phenotypes. Demographic differences between cases and controls
across cohorts were similar to the differences in the cohort
containing all PD cases shown in Table 1 (Supplementary Data 1).
Overview of signiﬁcant associations
We performed age-matched and sex-matched logistic regressions
between PD and 832 phenotypes, 436 of which were not highly
correlated with each other. Of these 436 associations, 132 were
statistically signiﬁcant after Bonferroni correction (P < 6.01 × 10−5),
122 of which remained signiﬁcant after adjusting for education,
income index, BMI, and tobacco use (Figs. 1, 2). We were able to
replicate 27 “known” associations (see Methods) that have
previously been reported in the literature. For example, we
replicated the negative association between caffeine intake and
PD (OR= 0.662 [95% CI 0.641–0.684], P= 3.60 × 10−136), and the
positive association between PD and constipation (OR= 5.31 [95%
CI 4.84–5.82], P= 6.19 × 10−272). The size of our cohort and the
diversity of phenotypes studied also allowed us to discover 42
novel associations that have not been previously reported. We
found 23 phenotypes that were strongly related to known aspects
of PD (“likely”) and 30 “unclear” phenotypes where an association
with PD has previously been studied, but did not meet our criteria
for being classiﬁed as “known” or “likely”.
Comparison with published associations
We investigated whether there were any known associations that
our analysis failed to detect. We compared our results with those
from a systematic review and meta-analysis of putative PD risk
factors6 (Supplementary Table 1). The comparison study found
19 signiﬁcant phenotypes, 10 of which had an analogous
phenotype in our PD phenome study. Our study successfully
replicated all 10 associations (P < 5 × 10−3 and concordant
direction of effect). For example, we replicated known negative
associations with hypertension (OR= 0.863 [95% CI 0.825–0.902],
P= 9.20 × 10−11) and alcohol consumption (for a 1 SD increase:
OR= 0.835 [95% CI 0.802–0.870], P= 6.33 × 10−18). We found that
PD was associated with living nearer to a farm (for a 1 SD increase
in distance: OR= 0.941 [95% CI 0.911–0.972], P= 2.22 × 10−4), but
this narrowly missed our study-wide signiﬁcance threshold of
6.01 × 10−5. The comparison study also highlighted 11 pheno-
types that were not signiﬁcantly associated with PD—possibly due
to insufﬁcient power—and 7 of them had an analogous
phenotype in our PD phenome study. The direction of effect
was similar in both studies for all phenotypes except for aspirin
use (23andMe study: OR= 0.825 [95% CI 0.766–0.889], comparison
study: OR= 1.11 [95% CI 0.93–1.32]).
DISCUSSION
Although Parkinson’s disease is diagnosed on the basis of motor
signs, the PD phenome is known to encompass a broad range of
non-motor features such as autonomic dysfunction, sleep
disturbances, cognitive dysfunction, and psychiatric disorders.
We systematically tested 832 phenotypes for an association with
PD and found 122 signiﬁcant associations. Some associations
represent known consequences of PD symptoms (e.g., trouble
walking, more frequent physician visits), known consequences of
PD treatment (e.g., having had brain surgery, daytime sleepiness
due to dopaminergic medication7), or plausible consequences of
later-stage PD (e.g., ﬂossing less frequently, less able to clap to a
beat). Other associated phenotypes are used in the International
Parkinson and Movement Disorder Society research criteria for
prodromal Parkinson’s disease8 (e.g., REM sleep behavior disorder,
olfactory loss). We also identiﬁed associations where the under-
lying causal relationship is unknown. We have organized PD-
associated traits into functionally related groups and discuss some
of the main ﬁndings here.
Several neurological disorders were associated with PD includ-
ing restless leg syndrome (RLS), migraine, and epilepsy. RLS is
more prevalent in people with PD, although previous prevalence
estimates have ranged widely and it is unclear whether RLS is a
risk factor for PD.9
We observed that migraine was positively associated with PD.
Only two cohort studies have previously been conducted, but
both found that midlife migraine was associated with increased
risk of PD.10,11 Both studies corrected for head trauma and
cardiovascular risk factors and disease since they are risk factors
for secondary parkinsonism. We found that most cardiovascular
variables were negatively associated with PD (e.g., high choles-
terol, BMI, tobacco use, type 2 diabetes) with the exception
of angina and chest pain during exercise. We found that
the association between PD and migraine remained signiﬁcant
Table 1. Demographics of PD cases and controls
Cases Controls P
N N
Age, mean (SD), years 69.8 (11.2) 13,196 69.3 (11.4) 131,960 3.10 × 10−6
Female, no. (%) 5,126 (38.8%) 13,196 51,260 (38.8%) 131,960 1
Education level, no. (%) 2.27 × 10−5
Less than high school 93 (1.1%) 8,159 1,537 (1.2%) 130,544
High school diploma 697 (8.5%) 8,159 12,198 (9.3%) 130,544
Associate’s degree/vocational degree/some college 1,954 (23.9%) 8,159 33,909 (26.0%) 130,544
Bachelor’s degree 2,391 (29.3%) 8,159 36,276 (27.8%) 130,544
Master’s/professional degree 2,475 (30.3%) 8,159 37,830 (29.0%) 130,544
Doctorate degree 549 (6.7%) 8,159 8794 (6.7%) 130,544
Income indexa, median (IQR), US dollars $66,486 ($36,937) 6,872 $66,489 ($37,023) 109,952 3.06 × 10−1
Body mass index, median (IQR), kg/m2 25.8 (6.1) 10,584 26.6 (6.1) 148,176 8.31 × 10−81
Tobacco use, no. (%) 4,085 (38.4%) 10,630 64,719 (46.8%) 138,190 1.21 × 10−63
SD standard deviation, IQR interquartile range, N total number of individuals in a cohort
aEach individual was assigned an income index value equal to the median household income in the past 12 months in his or her self-reported zip code using
data from the U.S. Census Bureau’s most recent (2016) American Community Survey 5-Year Estimates
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(OR= 1.756 [1.554–1.985], P= 1.93 × 10−19) after correcting for
head injury, angina, and chest pain during exercise using dummy
variable imputation. Since the average age of onset is typically
much earlier for migraine than for PD, migraine may be a novel PD
risk factor.
People with PD were more likely to self-report having been
diagnosed with, or treated for, epilepsy or seizures. A recent British
study found a signiﬁcantly greater incidence rate ratio of epilepsy
in 23,086 PD cases and 92,343 matched controls, suggesting that
PD may be a risk factor for epilepsy.12
Psychiatric manifestations are common in PD. Questions
pertaining to depression and anxiety have been incorporated
into the MDS-UPDRS1 and psychosis has been found in up to 60%
of PD patients.13,14 There has been substantial interest in a
connection between obsessive-compulsive disorder (OCD) and PD
since both can be treated via deep brain stimulation, can be
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Fig. 1 Forest plot of odds ratios between Parkinson’s disease and associated phenotypes. Forest plot of the odds ratios (ORs) ± 95%
conﬁdence intervals (CIs) for 69 phenotypes from the following groups that were signiﬁcantly associated with PD: personality, neurological,
diet, autonomic, psychiatric, sleep, musculoskeletal, or cardiovascular/metabolic. Colors denote the extent to which an association between
PD and the phenotype had previously been studied. If the upper 95% CI of an association was greater than four, data are presented as text.
The dashed line represents an OR of one—no association with PD. To help clarify the directionality of associations, comprehensive phenotype
deﬁnitions can be found in the Supplementary Data 2. GERD, gastro-esophageal reﬂux disease; IBS, irritable bowel syndrome; REM, rapid eye
movement
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caused by viral encephalitis, and may involve dysfunction of the
basal ganglia.15 Kummer and Teixeira15 reviewed 11 studies of
OCD and OCD symptoms (OCS) in relation to PD and found several
methodological issues including small sample sizes (20–124 PD
cases) leading to a lack of statistical power. Indeed, four of the ﬁve
case-control studies assessed yielded non-signiﬁcant results. With
10,437 PD cases in this particular regression, our study was well-
powered to detect a positive association between PD and OCD
(P= 2.34 × 10−15).
People with PD tended to report being less quick to anger, less
outspoken, and less talkative. Our results are qualitatively similar
to previous observations, which have found that people with PD
tended to be less aggressive,16 more inhibited,17 and more
neurotic and introverted.18 Whether these personality differences
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Fig. 2 Forest plot of odds ratios between Parkinson’s disease and associated phenotypes. Forest plot of the odds ratios (ORs) ± 95%
conﬁdence intervals (CIs) for 53 phenotypes from the following groups that were signiﬁcantly associated with PD: environment, drug usage,
urinary/renal, morphology, immune, skin, sensation, reproductive, overall health, other, music, lifestyle, eyes, cancer, hair, or cosmetic surgery.
Colors denote the extent to which an association between PD and the phenotype had previously been studied. If the upper 95% CI of an
association was greater than four, data are presented as text. The dashed line represents an OR of one—no association with PD. To help clarify
the directionality of associations, comprehensive phenotype deﬁnitions can be found in the Supplementary Data 2. DDT,
dichlorodiphenyltrichloroethane; LASIK, laser-assisted in situ keratomileusis
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exist prior to PD diagnosis is controversial and may be due to
recall bias.19
People with PD were more likely to report a preference for, and
increased consumption of, sweet foods and beverages. There have
been few consistent associations between PD and the intake of
speciﬁc food items with the exception of coffee6 and perhaps
dairy products.20 However, a recent Italian study found a greater
intake of sweets in 600 people with PD compared to 600 age-
matched and sex-matched controls.21 A German case–control
study including 342 people with PD reported a greater intake of
sweets, cookies, and cakes.22 This was associated with time since
diagnosis, suggesting that altered food preferences may be a
feature of later stage PD.
Being married was associated with an increased odds of PD.
Compared to people who reported never having been married
and after adjusting for covariates including age, the odds of PD
were: (1) highest in people who were currently married (OR=
1.793 [1.609–1.999], P= 5.04 × 10−26), (2) attenuated in people
who were divorced (OR= 1.268 [1.108–1.450], P= 5.40 × 10−4),
and (3) abrogated in people who were widowed (OR= 1.029
[0.852–1.241], P= 0.771). We ran a phenome analysis with marital
status as the outcome variable and found that marriage was
largely negatively associated with a wide variety of diseases, with
PD being a notable exception (Supplementary Table 2). This
remained true when analyzing females and males separately.
These results suggest that the association with PD was unlikely to
be due to bias from over-reporting of disease history in married
individuals, but we cannot completely rule out the possibility that
prodromal features of PD like REM sleep behavior disorder may
lead spouses to encourage their partners to seek medical
consultation.
We found that seasonal allergies were associated with PD.
Although the immune system is known to play an important role
in PD,23 to our knowledge only two studies of PD and allergies
have been published. A retrospective case-control study found
that PD was positively associated with allergic rhinitis, but not
asthma or hayfever.24 A study using the Taiwan National Health
Insurance Research Database found a positive, but not signiﬁcant,
association between PD and allergic rhinitis (hazard ratio= 1.29
[0.97–1.72]).25 We found that PD was also associated with allergies
to plants and antibiotics, but not with allergies to food or animals
(Supplementary Data 1). Understanding the biological differences
between these different groups of allergies may allow us to hone
in on speciﬁc immunological pathways that contribute to PD risk.
Seasonal allergies typically develop early in life, but further
research is needed to determine whether having seasonal
allergies is a risk factor for PD. If so, it may be possible to
manipulate risk using immune-modulating drugs.
Now that we have identiﬁed phenotypes that are correlated
with PD it is also possible to test whether these phenotypes are
causes or consequences of the disease. Longitudinal prospective
cohort studies are often used to perform causal inference, but this
approach may be less appropriate in PD since neurodegeneration
may begin as long as 20 years before PD diagnosis.26 Alternatively,
Mendelian randomization is a causal inference method that
utilizes data from genome-wide association studies (GWASes) and
is not hampered by the lengthy prodromal phase of PD.27 We
have collected genetic data for all individuals used in this study
and will be able to explore causal inference in future work.
Even in the absence of a known causal relationship, phenotypes
that are correlated with PD can be used to predict PD as long as
the phenotype is enriched in PD cases prior to diagnosis. In many
cases, modern machine learning algorithms have been remarkably
successful in taking a large set of predictors (e.g., phenotypes)—
each weakly associated with the outcome (e.g., PD)—and
combining them into a single, strong predictive model.28 Indeed,
several algorithms have been developed to predict the risk of
developing PD using data derived from clinical tests, olfaction
tests, genotyping arrays, and online tests and surveys.8,29,30
Models based on data from online surveys or electronic health
records can be used for low-cost population-wide screening, and
may be a valuable tool for prioritizing individuals with a high
probability of developing PD for research purposes. Identifying
high-risk individuals may also be critically important for the
development of effective disease modifying therapies for PD.
Because a large proportion of the dopaminergic neurons in the
substantia nigra have already died by the time PD is typically
diagnosed,31 it may already be too late to intervene in the
pathological cascade. Interventional trials in high-risk individuals
may therefore be critical to the development of therapies that
slow or halt PD progression.
There were several limitations to our study. First, PD diagnoses
were self-reported and not conﬁrmed by a clinician. However, we
have previously shown that self-reported PD diagnosis was
equivalent to a telemedicine-based diagnosis by a neurologist in
100% of a sample of ﬁfty people with PD from the 23andMe
cohort.32 Furthermore, our PD cohort has been used extensively in
GWAS studies, contributing to the discovery of over 40 PD loci.33
However, as misdiagnosis is not uncommon even in a clinical
setting,34 our study likely includes a unknown proportion of
misdiagnosed individuals. Second, our analyses were restricted to
individuals of European ancestry and further work is needed to
determine whether our results are applicable to individuals from
other ethnic backgrounds. Third, as with any epidemiological
study, it is always possible that a subset of our associations were
driven by unmeasured confounding variables, such as the use of
PD medications. However, only 9 associations (6.4%) showed
evidence of being confounded by four important demographic
variables (education, income index, BMI, and tobacco use), two of
which showed relatively large differences between PD cases and
controls (BMI and tobacco use). Fourth, case–control studies may
be subject to recall bias, although this should be weaker for
phenotypes that have not been widely reported to be associated
with PD, such as those in the “novel” and “unclear” categories.
Fifth, our study lacked temporal data for most phenotypes and we
were therefore unable to determine whether they occurred prior
to PD diagnosis. Finally, each regression was performed in a
separate cohort, limiting our ability to make comparisons between
association tests. Despite these limitations, we were able to
replicate 27 known associations and—apart from known associa-
tions for which we lacked relevant survey data, such as well water
use—there was only one known association that we narrowly
failed to replicate.
Epidemiological studies have identiﬁed a wide range of motor
and non-motor phenotypes linked to PD. We successfully
reproduced much of the established PD phenome using a
systematic screen of a large database of online survey responses.
We validated 27 known associations and highlighted an additional
23 associations with a strong prior link to a known association. Of
the phenotypes that we tested that are part of the established PD
phenome, only one (living near a farm) narrowly failed to reach
signiﬁcance. In addition, our work extends the PD phenome by
discovering 42 novel associations and adding support to 30
associations that have previously been studied, but not in
sufﬁcient depth to be considered known or likely. Among these
30 unclear associations we found that migraine, OCD, and
seasonal allergies were associated with PD, all of which tend to
have an age of onset several decades before the average age of
diagnosis for PD and may therefore represent PD risk factors. The
novel phenotypic associations identiﬁed by our hypothesis-
generating approach should be followed up in additional
case–control studies, as well as in prospective cohort and
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Mendelian randomization studies. Having a better understanding
of the PD phenome may enable further studies that dissect the
molecular mechanisms that drive these associations, perform
causal inference to identify novel PD risk factors, and allow for the
development of low-cost survey-based population screening tools
to identify at-risk individuals.
METHODS
Study participants
People with PD were recruited through a targeted email campaign in
conjunction with the Michael J. Fox Foundation, The Parkinson’s Institute
and Clinical Center, and many other PD patient groups and clinics. Emails
or hard copy mailings were sent to all individuals who had registered with
these groups as PD patients. For a fuller description of recruitment,
screening, and genotyping see Do et al.35 In addition, individuals with PD
were identiﬁed via online surveys from customers of the personal genetics
company, 23andMe, Inc., who had consented to participate in research.
PD cases were individuals who self-reported having been diagnosed
with PD. We excluded people if they reported a change in diagnosis or
uncertainty about their diagnosis. We have previously shown that self-
reported PD case status is approximately as reliable as clinically-diagnosed
PD with 50 out of 50 cases conﬁrmed via telemedicine interview.32 Age-
and sex-matched controls were drawn from 23andMe research participants
who self-reported that they have not been diagnosed with PD. We
removed individuals who self-reported having ever been diagnosed with:
(1) an atypical parkinsonism (e.g., dementia with Lewy bodies, progressive
supranuclear palsy, multiple system atrophy, corticobasal degeneration) or
a non-parkinsonian tremor disorder; or (2) stroke, deep vein thrombosis, or
pulmonary embolism (to reduce the probability of including individuals
with vascular parkinsonism).
Determining unrelated individuals of European ancestry
We focused on European ancestry individuals because 88.9% of all people
with PD in the 23andMe database had >97% European ancestry and
because PD incidence and prevalence may differ by ethnicity.36,37 All study
participants were genotyped by 23andMe and ancestry composition was
performed as previously reported.38 A maximal set of unrelated individuals
was chosen for the analysis using a segmental identity-by-descent
estimation algorithm.39 Individuals were deﬁned as related if they shared
700 cM identity-by-descent, including regions where the two individuals
share either one or both genomic segments identical-by-descent. This level
of relatedness (roughly 20% of the genome) corresponds approximately to
the minimal expected sharing between ﬁrst cousins in an outbred
population.
Protocol approvals, registrations, and patient consents
All individuals provided written informed consent, and 23andMe’s human
subjects protocol was reviewed and approved by Ethical & Independent
Review Services, an AAHRPP-accredited institutional review board. This
study was conducted according to the principles set out in the Declaration
of Helsinki.
Phenotypic data
Phenotypic data (including PD status) were collected using web or mobile-
based surveys. Surveys were either developed by 23andMe scientists or
based on existing instruments published in the medical literature. All
phenotypes for which we have conducted a genome-wide association
study since January 1st, 2016 were included. In addition, we included
environmental exposures that are unlikely to have a strong genetic
component, such as pesticide use. We excluded phenotypes related to
covariates used in downstream analyses, drug efﬁcacy or side effects, and
phenotypes for which PD was an inclusion or exclusion criterion. We
excluded phenotypes for which there were fewer than 2000 PD cases or
fewer than 10,000 total individuals who had answered the survey
questions necessary to deﬁne the phenotype. We removed case-control
phenotypes if there were fewer than 30 cases who were also PD cases.
Finally, we excluded phenotypes where we could not assign at least one
age-matched and sex-matched control to each PD case. Phenotype
deﬁnitions are provided for phenotypes that were signiﬁcantly associated
with PD (Supplementary Data 2). Analyses were run on phenotypic data
collected between November 10th, 2007 and October 10th, 2017.
Age-matched and sex-matched controls
For each of the 832 phenotypes, we constructed a case–control cohort
including all PD cases who had responded to the survey question(s) used
to deﬁne the phenotype. We then selected as many age-matched and sex-
matched controls for each case as possible. Speciﬁcally, we (1) separated
cases by biological sex and divided each into ten evenly-populated age
bins; (2) determined the number of controls that fell into each
corresponding sex/age bin; (3) divided the number of controls in a bin
by the number of corresponding cases; (4) determined the minimum
number of available controls per case across all bins, a number which we
refer to here as n; and (5) randomly selected n age-matched and sex-
matched controls for each case.
Identifying signiﬁcant associations
For each of the 832 phenotypes, we performed a logistic regression using
R (version 3.2.2) with PD as the dependent variable and the phenotype in
question as the independent variable. All regressions were run using a
standard set of covariates: age, sex, date of entry into the research cohort
(split into 20 evenly populated bins, used to correct for differences in
demographics and available surveys over time), and the ﬁrst ﬁve genetic
principal components (used to correct for differences in ancestry). In order
to focus on phenotypes that were not highly correlated with each other,
we computed the partial correlation coefﬁcient between each possible pair
of phenotypes, a value ranging between −1 (perfectly anticorrelated) to 1
(perfectly correlated). For each pair of phenotypes where the absolute
value of the partial correlation coefﬁcient was greater than 0.25,
we removed the phenotype that was less strongly associated with PD
based on P value. To mitigate the risk of spurious associations with PD
arising through multiple comparisons, we imposed a Bonferroni-based
P value threshold based on all 832 regressions performed in this study
(6.01 × 10−5).
Correcting for demographic variables
To test whether signiﬁcant associations may have been driven by
demographic differences between PD cases and controls, we re-ran
regressions including education, income index, body mass index (BMI) and
tobacco use as covariates. Income index was deﬁned as the median
household income in the past 12 months in an individual’s self-reported
zip code using data from the U.S. Census Bureau’s most recent (2016)
American Community Survey 5-Year Estimates. For the minority of
individuals who had not answered the survey questions used to deﬁne a
given demographic variable, we imputed data using dummy variable
imputation. Across all regressions, the median percentages of imputed
data were 18% for education, 6% for tobacco, 4% for BMI, and 22% for
income index. Phenotypes that no longer passed our signiﬁcance
threshold (P > 6.01 × 10−5) were removed from subsequent analyses.
Classiﬁcation of associations based on previous literature
We used PubMed to perform a MEDLINE database search using the
keyword “Parkinson” and keywords to describe each signiﬁcant pheno-
type. We supplemented these PubMed searches with simple web searches.
We identiﬁed meta-analyses, review articles, cohort studies, and
case–control studies that tested for an association between the prevalence
(or incidence) of PD and the prevalence (or incidence) of the phenotype in
question. We extracted information regarding these associations from
publications that met our search criteria. For each association, one of the
authors (KH) manually assessed the results from all relevant publications
and assigned the association to one of four categories denoting the extent
to which the association has previously been studied: known, likely,
unclear, and novel. Another author (AJN) reviewed these assignments and
discrepancies in assignments between the authors were discussed until
consensus was reached.
An association was classiﬁed as “known” if: (1) the phenotype is used in
the Movement Disorder Society (MDS) criteria for PD40 or prodromal PD,8
or the MDS-sponsored revision of the Uniﬁed Parkinson’s Disease Rating
Scale (MDS-UPDRS)1; (2) a meta-analysis has found a signiﬁcant association;
or (3) a review article by domain experts asserted that an association is
known. “Likely” associations were those where we were unable to ﬁnd
previous literature that demonstrated an association, but where we
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achieved consensus agreement that the phenotype was strongly related to
“known” aspects of PD. “Unclear” associations were those that have been
previously been reported in the literature, but did not meet the
requirements for the “known” or “likely” categories. “Novel” associations
were those for which we could not ﬁnd any relevant literature.
Diseases associated with marriage
We repeated our phenome analysis using marital status as the dependent
variable. Rather than use age-matched and sex-matched controls,
however, we included ﬁve additional age covariates: age raised to the
power of two to age raised to the power of six.
Previous publication
This article has previously been published as a preprint: https://doi.org/
10.1101/270934
Reporting Summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
DATA AVAILABILITY
Model outputs for all 832 logistic regressions are provided as Supplementary
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